Aceneuramic acid - Nobelpharma/ Ultragenyx Pharmaceutical

Drug Profile

Aceneuramic acid - Nobelpharma/ Ultragenyx Pharmaceutical

Alternative Names: Ace-ER - Ultragenyx; Aceneuramic acid extended-release - Ultragenyx; Kepnetic; N-acetylneuraminic acid (anhydride) - Nobelpharma; NANA; Neu5Ac; NPC 09; SA-ER - Ultragenyx; Sialic acid; Sialic acid ER - Ultragenyx; Sialic acid extended release - Ultragenyx; UX 001 Sialic acid; UX-001; UX-001 SA-ER

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nobelpharma
  • Developer Hadassah Medical Organization; Japan Agency for Medical Research and Development; Nobelpharma; Tohoku University; Ultragenyx Pharmaceutical
  • Class Neuraminic acids; Sialic acids; Small molecules
  • Mechanism of Action Muscle protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nonaka distal myopathy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Nonaka distal myopathy
  • Phase II Thrombocytopenia

Most Recent Events

  • 01 Jun 2018 Ultragenyx Pharmaceutical terminates a phase II trial for Nonaka distal myopathy in USA, Canada and Bulgaria (PO) (NCT02731690)
  • 01 Jun 2018 Ultragenyx Pharmaceutical terminates a phase IIIb extension trial for Nonaka distal myopathy in USA, Canada, Israel, France, Italy, Bulgaria and United Kingdom (PO, Controlled-release) (NCT02736188)
  • 30 Sep 2017 Nobelpharma completes a phase II/III trial in Nonaka distal myopathy in Japan (PO) (UMIN000020683)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top